Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Cara Therapeutics Inc
Healthcare
P/NCAV
0.81x
Ticker
CARA
Exchange
NASDAQ
Country
United States
Close
0.71 $
Mkt Cap
38.3M $
EV
-13.5M $
NCAV Burn Rate
67.4%
Current Ratio
4.54
Debt/Equity
0.0
EV/REV
-0.64x
EV/EBIT
0.1x
EV/FCF
0.2x
Dilution
11.1% p.A
Total Net Income
-622.2M $
Cheapness
96.0%
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average